Corneal thickness recovers after CXL

Article

After a corneal collagen cross-linking (CXL) procedure a patient's cornea thins but then recovers towards original thickness.

After a corneal collagen cross-linking (CXL) procedure a patient's cornea thins but then recovers towards original thickness, according to a one-year follow-up study published in the Journals of Cataract and Refractive Surgery.

Dr Peter S. Hersh et al., Cornea and Laser Eye Institute, New Jersey, USA, studied 54 eyes with keratoconus and 28 eyes with ecstasia after LASIK. The outcome measures were corneal thickness at the apex, the thinnest point and the pupil centre. These were measured at baseline and 1, 3, 6 and 12 months post-CXL.

Mean preoperative thinnest pachymetry was 440.7 μm ± 52.9 SD. Apex and corneal thickness returned to baseline after 1 year. Corneal thickness recovered more rapidly in ecstasia patients than in keratoconus patients. Although the researchers found that the corneal thickness was reduced up to 3-months post-op, the baseline thickness was recovered at 3 to 6-months follow-up.

In conclusion, the baseline thickness of the cornea is recovered after CXL but the causes and possible effects of this change in thickness still need to be explained.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.